Before & After

Consistent RESULTS WHEREVER PATIENTS
NEED IT

ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use1,2

Not a steroid no boxed warning
Simple once-daily treatmentSimple once-daily treatment

For age 6+

For age 12+

FoamCream

ZORYVE CREAM. ONCE A DAY. ANYWHERE.

Review clinical trial photos of patients with plaque psoriasis treated with ZORYVE cream

Knee

KneeInframammary
CreaseElbowHeelShinFace & NeckAxillaKneeHand

ZORYVE CREAM. ONCE A DAY. ANYWHERE.

Review clinical trial photos of patients with plaque psoriasis treated with ZORYVE cream

Knee3

AGE 59, FEMALE

Actual clinical trial patient

Baseline: IGA = 3

Baseline: IGA = 3

Knee - Week 2 IGA = 2
Knee - Week 4 IGA = 2
Knee - Week 6 IGA = 1
Knee - Week 8 IGA = 1

Inframammary Crease3

AGE 59, FEMALE

Actual clinical trial patient

Baseline: I-IGA = 2

Baseline: I-IGA = 2

Inframammary Crease - Week 2 I-IGA = 2
Inframammary Crease - Week 4 I-IGA = 1
Inframammary Crease - Week 6 I-IGA = 0
Inframammary Crease - Week 8 I-IGA = 0

POWERFUL CLEARANCE IN HARD-TO-TREAT AREAS2

Elbow3

AGE 58, MALE

Actual clinical trial patient

Baseline: IGA = 4

Baseline: IGA = 4

Elbow - Week 2 IGA = 3
Elbow - Week 4 IGA = 2
Elbow - Week 6 IGA = 2
Elbow - Week 8 IGA = 1

Heel3

AGE 53, FEMALE

Actual clinical trial patient

Baseline: IGA = 3

Baseline: IGA = 3

Heel - Week 2 IGA = 1
Heel - Week 4 IGA = 1
Heel - Week 6 IGA = 0
Heel - Week 8 IGA = 1

Shin3

AGE 61, FEMALE

Actual clinical trial patient

Baseline: IGA = 3

Baseline: IGA = 3

Shin - Week 2 IGA = 2
Shin - Week 4 IGA = 1
Shin - Week 6 IGA = 0
Shin - Week 8 IGA = 0

Secondary Endpoint

6x

as many patients with knee or elbow involvement achieved IGA of Clear (0) or Almost
Clear (1) with ZORYVE cream (49%, n=446) at Week 8 vs vehicle (8%, n=226)4

CLEARANCE ANYWHERE PATIENTS NEED IT2

Face & Neck3

AGE 54, MALE

Actual clinical trial patient

Baseline: IGA = 3

Baseline: IGA = 3

Face & Neck - Week 2 IGA = 2
Face & Neck - Week 4 IGA = 1
Face & Neck - Week 6 IGA = 0
Face & Neck - Week 8 IGA = 1

Axilla3

AGE 60, MALE

Actual clinical trial patient

Baseline: I-IGA = 3

Baseline: I-IGA = 3

Week 2: I-IGA = 3
Week 4: I-IGA = 2
Week 6: I-IGA = 0
Week 8: I-IGA = 0

AGE 37, MALE

Actual clinical trial patient

Baseline: I-IGA = 3

Baseline: I-IGA = 3

Week 2: I-IGA = 1
Week 4: I-IGA = 0
Week 6: I-IGA = 0
Week 8: I-IGA = 0

ZORYVE is the only branded topical for plaque psoriasis specifically
indicated for use in the intertriginous areas2,3

Meaningful clearance at Week 8

These patients met 2-grade improvement on IGA score but did not achieve Clear (0) or Almost Clear (1) at Week 83

Knee3

AGE 60, MALE

Actual clinical trial patient

Baseline: IGA = 4

Baseline: IGA = 4

Knee - Week 8 IGA = 2

Week 8: IGA = 2

Hand3

AGE 50, MALE

Actual clinical trial patient

Baseline: IGA = 4

Baseline: IGA = 4

Hand - Week 8 IGA = 2

Week 8: IGA = 2

IGA Scale: 4 = Severe, 3 = Moderate,
2 = Mild, 1 = Almost Clear, 0 = Clear.
B-IGA Scale: 4 = Severe, 3 = Moderate,
2 = Mild, 1 = Almost Clear, 0 = Clear.

Did you know? Banner ImageDid you know? Banner Image

In a 2021 survey of >500 plaque psoriasis patients, more than 4 OUT OF 5 TOPICAL USERS (81%) wished they had more topical treatment alternatives to steroids.3*

*This survey was conducted online by The Harris Poll on behalf of Arcutis Biotherapeutics among US adults 18+ who have been diagnosed with psoriasis by a healthcare provider. The survey was conducted in 2021, among 507 plaque psoriasis patients. Figures were weighted where necessary to bring the data into line with actual proportions in the population using a multi-step weighting process.

See the
Clearance Data

Learn About
The Formulation

Request a
Representative